WEE1 and non-small cell lung carcinoma: Accordingly, the WEE1 inhibitor AZD1775 sensitizes gastric [122], non-small cell lung cancer (NSCLC) [123], and pancreatic cancer [124] to olaparib, particularly when combined with genotoxic stress via ionizing radiation, and a small number of clinical trials are currently underway (Table 2).